BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//REMEDi4ALL - ECPv6.17.4.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://remedi4all.org
X-WR-CALDESC:Events for REMEDi4ALL
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Amsterdam
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20280326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20281029T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Amsterdam:20260630T103000
DTEND;TZID=Europe/Amsterdam:20260630T123000
DTSTAMP:20260622T145259Z
CREATED:20260622T145259Z
LAST-MODIFIED:20260622T145259Z
UID:19454-1782815400-1782822600@remedi4all.org
SUMMARY:BioMed21 Webinar: Rare Disease Research and Drug Development with NAMs in the EU
DESCRIPTION:Exploring human-relevant in vitro and in silico approaches for disease modelling and therapeutic innovation \nWebinar description \nBioMed21 (Biomedical Research for the 21st Century Collaboration) invites you to a 60-minute webinar exploring how New Approach Methodologies (NAMs)\, including advanced human-relevant in vitro models and in silico technologies\, are transforming rare disease research and drug development. \nThe webinar will bring together experts from academia\, policy\, and biomedical research to discuss innovative approaches ranging from retinal organoids and retina-on-chip systems to computational modelling and AI-driven strategies for therapy development. \nTopics will include: \n\nHuman-centric strategies for rare disease research\nhiPSC-derived organoids and organ-on-chip technologies\nIn silico modelling and computational approaches\nTranslational opportunities and challenges for NAMs in therapy development\nEuropean research and policy perspectives\n\nDraft agenda \n\nAdvancing Human-Centric Strategies for Rare Disease Research: A European Research Policy Perspective\nFrancesca Pistollato – Humane World for Animals\nHuman retinal organoids and retina-chip platform for modeling disease and gene therapy\nKevin Achberger – University of Tübingen\nHuman-Centric In Silico Modeling for Rare Disease Research and Drug Development\nFrancesco Pappalardo – University of Catania & the COMBINE Group\nNAMs in Rare Disease Therapy Development: Where and When Do They Fit?\nManoe Janssen – Radboudumc\n\n📄 BioMed21 Policy Paper: https://biomed21.org/wp-content/uploads/2026/05/RareDiseases_WhitePaper_2026-final.pdf \n\n\n\nRegister for the webinar here!
URL:https://remedi4all.org/event/biomed21-webinar-rare-disease-research-and-drug-development-with-nams-in-the-eu/
LOCATION:Online Event
ATTACH;FMTTYPE=image/png:https://remedi4all.org/wp-content/uploads/2026/06/Diseno-sin-titulo-e1781530718337.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Amsterdam:20260716T110000
DTEND;TZID=Europe/Amsterdam:20260716T123000
DTSTAMP:20260612T075224Z
CREATED:20260612T075106Z
LAST-MODIFIED:20260612T075224Z
UID:19370-1784199600-1784205000@remedi4all.org
SUMMARY:Webinar: Understanding the Value of your Repurposed Medicine
DESCRIPTION:An introduction to HTA\, Early HTA\, and patient preference evidence for demonstrating the value of repurposed medicines. \n\n\n\n\nRepurposing has the potential to bring treatments to patients more quickly and efficiently. However\, the success of a repurposed medicine depends not only on its clinical effectiveness\, but also on demonstrating its value to healthcare decision-makers and ensuring patient access. \nHealth Technology Assessment (HTA) is the process used to evaluate the value of a health intervention or technology and inform reimbursement and healthcare decision-making. \nJoin experts from the Syreon Research Institute for an introduction to HTA and Early HTA\, and learn how these approaches can support the development\, assessment\, and value maximisation of repurposed medicines. \nThe webinar will also explore the role of patient preferences in value assessment\, using case studies to showcase the importance of incorporating patient perspectives to strengthen evidence generation and support patient-centred decision-making. \nRegister for the webinar here!
URL:https://remedi4all.org/event/webinar-understanding-the-value-of-your-repurposed-medicine/
LOCATION:Online Event
ATTACH;FMTTYPE=image/png:https://remedi4all.org/wp-content/uploads/2026/06/CT-Webinar-Series-Webinar-1-FINAL.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Amsterdam:20260906T140000
DTEND;TZID=Europe/Amsterdam:20260911T170000
DTSTAMP:20260325T092254Z
CREATED:20260225T154749Z
LAST-MODIFIED:20260325T092254Z
UID:17899-1788703200-1789146000@remedi4all.org
SUMMARY:2026 REMEDi4ALL Hackathon
DESCRIPTION:Are you an early career researcher (ECR) who wants to delve into drug repurposing?\n  \nJoin us for the third REMEDi4ALL Hackathon\, 6-11 September 2026\, held at Hotel Checkin Montserrat\, near Barcelona\, Spain. \nThe REMEDi4ALL Repurposing Hackathon is designed to help early career researchers learn by doing. Join a small team of international trainees keen to learn about the repurposing pathway on a week-long residential course where you aim to plan the development of a repurposing candidate for a specific patient community.  \nWho is the Hackathon for?\n\nStudents and researchers in the early stages of their career up to 2 years post-doc\nIndividuals with an interest in drug repurposing\nIndividuals with an excellent scientific track record\nPrevious experience in the drug repurposing field will be considered a plus\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWhat will you learn?\nThe REMEDi4ALL Hackathon aims to teach participants how to: \n\nUse computational tools to generate repurposing candidates suitable for a defined indication\nNarrow down potential repurposed drug options tailored to a particular indication\nIdentify needs and knowledge gaps in a repurposing project\, helping to define the path for a drug candidate\nWork together with other ECRs to complete a repurposing challenge\n\n\n  \n\nTraining format\n\n\n\nIn-person\, residential training for 15 participants\nAdvance registration required\nSmall teams of early career researchers work on a project throughout the week\nSupport through lectures and guidance of REMEDi4ALL experts\, and external advisers\, including patient experts\n\n\n\n\n\n  \nInterested in learning more? Check out our highlights video from 2025 or explore the Hackathon website within the REMEDi4ALL Repurposing Academy.\nApplications open now: apply here
URL:https://remedi4all.org/event/2026-remedi4all-hackathon/
LOCATION:Hotel Checkin Montserrat\, Carrer Querol\, 08293 Collbató\, Barcelona\, Spain
ATTACH;FMTTYPE=image/jpeg:https://remedi4all.org/wp-content/uploads/2025/10/image00005-1-scaled.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Amsterdam:20260908T170000
DTEND;TZID=Europe/Amsterdam:20260908T183000
DTSTAMP:20260907T064805Z
CREATED:20260907T064414Z
LAST-MODIFIED:20260907T064805Z
UID:20044-1788886800-1788892200@remedi4all.org
SUMMARY:Improved Patient\, Carer and Clinician Involvement in EU HTA from Hungary
DESCRIPTION:The Hungarian Health Economics Association (META) is pleased to invite patients\, carers\, patient organisation representatives\, clinicians\, HTA professionals and other interested stakeholders to its next online webinar. \nThe participation of Hungarian patients and clinical experts in EU-level Joint Clinical Assessments and Joint Scientific Consultations has so far remained limited\, which may reduce the local relevance and uptake of EU HTA outputs and could also hinder meaningful patient and expert participation in national HTA processes. \nThe presentation section will explain how patients\, carers and clinicians can contribute to EU HTA\, how potential contributors are identified\, and how they can prepare for and improve their chances of being selected for these roles. \nConfirmed speakers: \n\nJulie Spony\, representing the European Commission’s DG SANTE\nJulien Delaye\, Brussels Centre for Collaboration in Health\n\nTheir presentations will be followed by a moderated discussion with participants. \nThe event will also launch a public consultation on a Hungarian-language practical guide being developed by HHEA. The document explains the available opportunities for involvement\, the respective roles and responsibilities\, how potential contributors are identified and selected\, and the key practical considerations for preparing to participate effectively. The guide is so far based on the EU HTA Regulation and related methodological and procedural documentation\, complemented by internationally recognised guidance\, competency frameworks and good practices. The Hungarian community’s contribution would help ensure that\, alongside the relevant European regulatory and methodological requirements\, the guide adequately reflects Hungarian experience and the practical needs of patients\, carers and clinical experts. \nLearn more and register here.
URL:https://remedi4all.org/event/improved-patient-carer-and-clinician-involvement-in-eu-hta-from-hungary/
ATTACH;FMTTYPE=image/png:https://remedi4all.org/wp-content/uploads/2026/09/Hungary.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Amsterdam:20261013T160000
DTEND;TZID=Europe/Amsterdam:20261013T170000
DTSTAMP:20260901T134555Z
CREATED:20260901T134555Z
LAST-MODIFIED:20260901T134555Z
UID:19956-1791907200-1791910800@remedi4all.org
SUMMARY:How do you design a clinical study that is registration-ready?
DESCRIPTION:A study that is suitable for publication or guideline development is not automatically suitable for marketing authorisation. Hellen Houlleberghs\, Orfenix’ s clinical director will discuss what changes when the goal is registration of a product instead of just a publication. She will discuss what changes including: study design and endpoints\, study preparation\, CTIS readiness\, GCP\, IMP logistics\, common pitfalls\, timelines\, and post-study obligations. \nParticipants will also receive the “From protocol to registration readiness scan”\, a practical tool to identify potential gaps in their own study. \nVisit the website for more information: https://orfenix.com/webinar-how-do-you-design-a-clinical-study-that-is-registration-ready/ \n Registration link: https://events.teams.microsoft.com/event/b00fe972-6382-435a-8b8c-19b6abf772f0@5b8666c1-d3a4-4d81-841c-691b9585ca11
URL:https://remedi4all.org/event/how-do-you-design-a-clinical-study-that-is-registration-ready/
LOCATION:Webinar
ATTACH;FMTTYPE=image/png:https://remedi4all.org/wp-content/uploads/2026/09/Or_webinar-2-hellen-clinical-featured-image-980x551-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270610
DTEND;VALUE=DATE:20270612
DTSTAMP:20260831T133918Z
CREATED:20260831T133918Z
LAST-MODIFIED:20260831T133918Z
UID:19944-1812585600-1812758399@remedi4all.org
SUMMARY:Repurposing Bootcamp for Patient Representatives
DESCRIPTION:Join the REMEDi4ALL Repurposing Bootcamp and lead the way in innovative treatment strategies.\nThe REMEDi4ALL Repurposing Bootcamp is a specialised training programme designed to empower patient representatives with the essential knowledge and tools to drive innovation through drug repurposing. Our mission is to equip you with the skills and expertise needed to lead efforts in identifying and promoting new therapeutic uses for existing drugs\, ultimately improving access to effective treatments and transforming patient care.  \nOur training programme will offer a comprehensive learning experience through a blend of in-person lectures\, workshops and discussions supported by virtual training materials that will be available soon in our digital academy. Our live programme will cover key aspects of drug repurposing\, including regulatory pathways\, clinical trials\, and patient engagement strategies all curated to ensure maximum relevance to patient group leaders.  \nLearn more here.
URL:https://remedi4all.org/event/repurposing-bootcamp-for-patient-representatives/
LOCATION:Hotel SB BCN Events\, Castelldefels\, Barcelona\, Spain
ATTACH;FMTTYPE=image/png:https://remedi4all.org/wp-content/uploads/2026/08/PatientBootcamp2027.png
END:VEVENT
END:VCALENDAR